Sumanta K. Pal, MD: Does Adding Berzosertib to Chemotherapy Improve Outcomes in Urothelial Carcinoma?

Posted: Tuesday, June 15, 2021

Sumanta K. Pal, MD, of City of Hope, discusses the clinical implications of findings from a phase II study that showed no improvement in progression-free survival with the addition of berzosertib, an ATR inhibitor, to platinum-based chemotherapy in patients with advanced urothelial carcinoma.